Ionis Pharmaceuticals Inc
Company Profile
Business description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Contact
2855 Gazelle Court
CarlsbadCA92010
USAT: +1 760 931-9200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
927
Ionis Pharmaceuticals Inc News & Analysis
stocks
5 undervalued US stocks that crushed earnings
stocks
Global healthcare stocks for your watchlist
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,450.90 | 64.30 | -0.76% |
| CAC 40 | 7,240.70 | 13.72 | 0.19% |
| DAX 40 | 19,068.76 | 35.12 | 0.18% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,035.12 | 9.35 | 0.12% |
| HKSE | 19,823.45 | 23.43 | -0.12% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 38,721.66 | 654.43 | -1.66% |
| NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,193.40 | 62.20 | -0.75% |
| SSE Composite Index | 3,439.28 | 17.31 | 0.51% |